Our PepMix Peptide Pools put to Action: read-up!

For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Our PepMix Peptide Pools put to Action: read-up!

Published on 09/06/2023

JPT offers the largest variety of ready-to-use overlapping PepMix Peptide Pools, which cover infectious disease, tumor-associated, or allergy-, and autoimmune-specific antigens. The following reading selection includes a very recent pick of the more than 700 PepMix publications available on our website.

Age-related Differences in Immune Reactions to SARS-CoV-2 Spike and Nucleocapsid Antigens Morhart et al,. Vaccines (2023) Products used: PepMix CEFX Ultra SuperStim Pool & PepMix Human (Actin)

A Systems Immunology Study comparing innate and adaptive Immune Responses in Adults to COVID-19 mRNA and Adenovirus Vectored Vaccines Ryan et al., Cell Reports Medicine (2023) Product used: PepMix Chimpanzee Adenovirus Y25 (Hexon Protein)

The Role of the T-cell mediated Immune Response to Cytomegalovirus Infection in Intrauterine Transmission Soriano-Ramos et al., PLOS One (2023) Products used: PepMix HCMVA (IE-1) & HCMVA (pp65)

Personalized RNA Neoantigen Vaccines stimulate T cells in Pancreatic Cancer Rojas et al., Nature (2023) Products used: custom PepMix

A cell-free antigen processing system informs HIV-1 epitope selection and vaccine design Sengupta et al., Journal of Experimental Medicine (2023) Products used: PepMix™ HIV-1 (NEF) Ultra, PepMix HIV-1 (Con B gag motif)

Combination Ad26.RSV.preF/preF Protein Vaccine induces Superior Protective Immunity compared with Individual Vaccine Components in Preclinical Models Saeland et al., Vaccines (2023) Product used: PepMix HRSVA (Fusion Glycoprotein F0)

Validation of the Performance and Suitability of a new Class of FBS optimized for Use in Single-cell Functional Assays Berrong et al., Journal of Immunological Methods (2023) Products used: CEF Pool (extended), CEFT MHC-II Pool, PepMix HCMVA (pp65)

Complete manufacture and QC according to stringent IS0 9001:2015 regulations

Our antigen spanning peptide pools are guaranteed to cover the entire protein while maintaining consistent peptide length within the pool

Peptide purity and content is verified and documented for each peptide and final pool

To avoid potentially interfering de novo epitope formation during peptide synthesis we always add a capping process per default

PepMix Peptide Pools covering antigens of various infectious pathogens

PepMix Peptide Pools for tumor-associated antigens

PepMix Control Pools to establish reliable and validated T cell assays

Pan Select PepMix cover immune-dominant epitopes within one organism

PepMix Ultra Pools are designed to address sequence diversity in genetically heterogeneous pathogens

PepMix Collections are a combination of peptide pools belonging to either one organism or condition

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Research context

Read sources and limitations before applying a claim.

JPT's Tumor Associated Antigens for Research

PepMix™ Peptide Pools are instrumental in cancer immunotherapy, particularly for exploring tumor-associated antigens and improving T cell responses. JPT’s PepMix™ Peptide Pools support the development of novel cancer vaccines and therapeutic strategies targeting tumor-specific markers. Below, you will find key studies referencing JPT’s PepMix™ Peptide Pools in research.

Source: jpt.com ↗

TCR-T Research with PepMix™ Peptide Pools for Key Cancer Targets

Published on 15/05/2025 T-cell receptor-engineered T-cell therapy (TCR-T) is rapidly gaining momentum in the field of cancer immunotherapy. Unlike CAR-T cells, which recognize surface antigens, TCR-T cells can detect and eliminate cancer cells based on intracellular tumor-associated antigens presented by MHC molecules, offering broader therapeutic opportunities across solid and hematologic malignancies. A recent comprehensive review (Zhang et al., 2023) highlights the 16 major cancer targets currently pursued in TCR-T clinical trials. JPT is proud to support researchers in this exciting field by offering PepMix™ Peptide Pools for 15 of these 16 critical targets — and a partial PepMix™ for the remaining one (EGFRvIII). Main TCR-T Targets Available as PepMix™ Peptide Pools: AFP (Alpha-fetoprotein) EGFRvIII (partially available as ErbB2-ICD and ErbB2-ECD) EBV (Epstein-Barr Virus) HA-1 HBV (Hepatitis B Virus) HPV (Human Papillomavirus) KK-LC-1 KRAS (mutated) MAGE-A1 MAGE-A3 MAGE-A4 MAGE-A10 MART-1 Mesothelin NY-ESO-1 WT1 Check all our tumor-associated antigen peptide pools and our more than 1500 individual epitope peptides. Why Choose PepMix™ Peptide Pools for TCR-T Research? Comprehensive Antigen Coverage: Each PepMix™ consists of overlapping peptides that span the full protein sequence, ensuring maximal coverage of known and novel epitopes — ideal for discovery, monitoring, and functional assays. High Quality and Batch Consistency: Our optimized synthesis and stringent QC processes guarantee high purity, reproducibility, and biological performance you can trust for clinical research. Experience with Difficult Sequences: Hydrophobic and aggregation-prone sequences? No problem. JPT’s proven expertise ensures even challenging targets are fully represented in your peptide pool. Immediate Availability: More than 450 different catalog PepMix™ peptide pools are available from stock — enabling faster project initiation and smoother workflows. In case we do not have you antigen, contact us! We can provide it to you as a custom PepMix™ Peptide Pool. Accelerate Your TCR-T Research PepMix™ Peptide Pools are widely used for: Screening TCRs for target specificity Monitoring T-cell responses post-infusion Identifying immunodominant epitopes Supporting preclinical and translational studies Advance your TCR-T programs with reliable tools trusted by researchers worldwide and learn more about The World of PepMix™ or contact us!

Source: jpt.com ↗

Practical and safety references

These excerpts are educational, not personalised medical instructions.

Potential benefits

Benefits of Custom PepMix™ Peptide Pools

Overlapping peptide pools are preferable to whole proteins for antigen-specific T-cell stimulation because: Simultaneous detection of CD4+ and CD8+ responses in a single sample Equivalent or better stimulation T-cell responses compared to whole protein antigens Antigen spanning peptide pools stimulate T-cells in an HLA independent manner All epitopes covered, epitope spreading addressed Purified peptide pools eliminate risk of toxic inhibition of T-cell responses No false positive T-cell stimulation caused by deletion peptides Superior control compared to phytohemagglutinin (PHA) and concanavalin A (ConA) Improved responses in stored blood and PBM cells compared to whole proteins High-batch-to-batch reproducibility Reliable chemical and biochemical quality control and quality assurance for peptide synthesis and peptide pool generation Prolonged shelf stability when stored freeze dried

Source: jpt.com ↗

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Our PepMix Peptide Pools put to Action: read-up!

JPT's Tumor Associated Antigens for Research

TCR-T Research with PepMix™ Peptide Pools for Key Cancer Targets

Benefits of Custom PepMix™ Peptide Pools

Peptide Therapy Guide Editorial Team

Custom SIL peptides - peptide pools

Custom PepMix™ Peptide Pools | JPT

Visit the Whole Wide World of Peptide Pools

This February: RSV Peptide Pools & Arrays 20% OFF